WO2006009143A1 - Process for production of (3s)-3-hydroxymethyl-7-oxo- pyridobenzoxazine-6-carboxylic esters - Google Patents

Process for production of (3s)-3-hydroxymethyl-7-oxo- pyridobenzoxazine-6-carboxylic esters Download PDF

Info

Publication number
WO2006009143A1
WO2006009143A1 PCT/JP2005/013251 JP2005013251W WO2006009143A1 WO 2006009143 A1 WO2006009143 A1 WO 2006009143A1 JP 2005013251 W JP2005013251 W JP 2005013251W WO 2006009143 A1 WO2006009143 A1 WO 2006009143A1
Authority
WO
WIPO (PCT)
Prior art keywords
general formula
hydroxymethyl
chemical
oxopyridobenzoxazine
carboxylic acid
Prior art date
Application number
PCT/JP2005/013251
Other languages
French (fr)
Japanese (ja)
Inventor
Yoshikazu Asahina
Tetsuya Kimura
Original Assignee
Kyorin Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co., Ltd. filed Critical Kyorin Pharmaceutical Co., Ltd.
Priority to JP2006529225A priority Critical patent/JPWO2006009143A1/en
Publication of WO2006009143A1 publication Critical patent/WO2006009143A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00Asymmetric syntheses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems

Definitions

  • the present invention is a 4-substituted 3-cyclopropylaminomethyl virylidine which is effective against resistant bacteria, because the conventional antibacterial agent which does not only exhibit a safe and strong antibacterial activity is effective.
  • -(3R) -3-Fluoromethyl-7-oxopyridobenzoxazine with 6-groups (6S) (3S) -3-Hydroxymethyl-7-oxopyridobenzoxazine, an intermediate of rubonic acid derivatives It relates to a method for producing a 6-carboxylic acid ester derivative.
  • MRSA methicillin-resistant Staphylococcus aureus
  • PRSP penicillin-resistant Streptococcus pneumoniae
  • VRE vancomycin-resistant enterococci
  • QRSA Staphylococcus aureus
  • Patent Document 1 WO03Z078439 Nonfret
  • Patent Document 2 JP 59-1489
  • Non-patent literature l Chem. Pharm. Bull, 1987, 35, 1896-1902.
  • the problem to be solved by the present invention is that a conventional antibacterial agent that not only exhibits a safe and strong antibacterial action, but is not effective.
  • (3R) 3-Hydroxymethyl-7-oxopyridobenzox, which is an intermediate of (3R) — 3-Fluoromethyl-7-oxopyridobenzoxazine 6-strength rubonic acid derivative with propyl aminomethyl virylyl group It is an object of the present invention to provide an industrially excellent method for producing sasine-6-carboxylic acid ester derivatives.
  • the present invention relates to the general formula (1)
  • 6-strength rubonic acid ester derivatives can be produced industrially safely and inexpensively, this compound is used as a raw material for 4-substituted 3-cyclopropylaminomethyl virylylol, which has excellent antibacterial activity and safety against resistant bacteria.
  • a (3R) -3-fluoromethyl-7-oxopyridobenzoxazine 6-carboxylic acid derivative having a group can be produced industrially safely and inexpensively.
  • an orthoformate such as ethyl orthoformate is added to a benzoyl acetate derivative represented by the general formula (1) in the presence of a carboxylic acid anhydride such as acetic anhydride.
  • the mixture is stirred at a temperature of 0 to 200 ° C, preferably 50 to 150 ° C, usually 10 minutes to 50 hours, preferably 1 hour to 10 hours, and then expressed by the above formula (2) (2R ) 2
  • the aminopropanol derivative is mixed and stirred in an appropriate solvent at a temperature of usually 0 to 150 ° C, preferably 0 to 100 ° C, usually 10 minutes to 50 hours, preferably 30 minutes to 10 hours. And can be implemented.
  • Examples of the lower alkyl group represented by R1 in the general formula (1) include a methyl group, an ethyl group, a propyl group, an isopropyl group, and a cyclopropyl group.
  • examples of the lower alkyl group represented by R2 include a methyl group, an ethyl group, a propyl group, an isopropyl group, a tert butyl group, and a benzyl group.
  • examples of the halogen atom in X in the general formula (1) include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
  • examples of the halogen atom for Y include a fluorine atom and a chlorine atom. And bromine atom or iodine atom.
  • the orthoformate ester, the carboxylic acid anhydride and the compound represented by the formula (2) are used in an amount of equimolar or more, preferably 1 to 10 moles relative to the compound of the general formula (1). Can be used in proportion of quantity. Any solvent can be used as the solvent used in this reaction as long as it does not affect the reaction.
  • aromatic hydrocarbons such as benzene, toluene, xylene, etc .
  • jetyl ether, diisopropyl ether Ethers such as tetrahydrofuran and dioxane
  • aliphatic hydrocarbons such as pentane and hexane
  • halogenated hydrocarbons such as dichloromethane and chloroform
  • alcohols such as methanol, ethanol and propanol
  • dimethylformamide Amides such as 1-methyl-2-pyrrolidone
  • sulfoxides such as dimethyl sulfoxide.
  • the second step of the method of the present invention is a 2-benzoyl 3-[(2R) represented by the general formula (3).
  • -2- [3- (2-Tetrahydrovinyl) mono 1-hydroxy] propyl] aminoacrylic acid ester derivative is usually 0 to 200 ° C., preferably 0 to 150 in the presence or absence of a base. It is usually carried out by mixing and stirring at a temperature of ° C for 10 minutes to 50 hours, preferably 30 minutes to 24 hours.
  • the base used in this reaction include metal hydrides such as sodium hydride, potassium hydride, and calcium hydride; sodium hydroxide, sodium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, and the like.
  • Alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide; metal fluorides such as sodium fluoride, potassium fluoride, cesium fluoride; triethylamine, diisopropylpropylamine, 1,8 diazabicyclo Organic bases such as 5, 4, 0] unde. These bases are usually used in an amount of equimolar or more, preferably 1 to 2 times the molar amount of the compound represented by the general formula (3).
  • any solvent that does not affect the reaction can be used.
  • aromatic hydrocarbons such as benzene, toluene, xylene, etc .
  • Ethers such as diisopropyl ether, tetrahydrofuran and dioxane
  • aliphatic hydrocarbons such as pentane and hexane
  • halogenated hydrocarbons such as dichloromethane and chloroform
  • alcohols such as methanol, ethanol and propanol
  • dimethyl Amides such as formamide and 1-methyl 2-pyrrolidone
  • dimethylsulfo And sulfoxides such as xoxide.
  • the (3R) -3- (2-tetrahydrobiral) oxymethylpyridobenzoxazine carboxylic acid ester derivative represented by the general formula (3) is used.
  • This is a process for producing a (3S) -3-hydroxymethyl-7oxopyridobenzoxazine 6-carboxylic acid ester derivative represented by the general formula (4) by eliminating 2-tetrahydrobiral group. .
  • the compound represented by the general formula (3) is usually used in the absence of a solvent or in an appropriate solvent with an acid. It is carried out by mixing and stirring at a temperature of 0 to 200 ° C, preferably 0 to 150 ° C, usually 10 minutes to 50 hours, preferably 30 minutes to 24 hours.
  • the acid used in this reaction include inorganic acids such as hydrochloric acid, sulfuric acid, hydrobromic acid, and phosphoric acid; organic acids such as formic acid, acetic acid, trifluoroacetic acid, p-toluenesulfonic acid, and methanesulfonic acid. .
  • any solvent that does not affect the reaction can be used.
  • water any solvent that does not affect the reaction
  • alcohols such as methanol, ethanol, and propanol
  • ethers such as tetrahydrofuran and dioxane.
  • ketones such as acetone and methyl ethyl ketone, and these solvents are used alone or in combination.
  • racemic 2-aminopropanol derivative is used as a starting material according to the method of the present invention, a racemic 3-hydroxymethyl-7-oxopyridobenzoxazine 6-carboxylate derivative is obtained. If a (2S) -2 aminopropanol derivative is used, a (3R) -3-hydroxymethyl-7-oxopyridobenzoxazine-6-carboxylic acid ester derivative can be produced.
  • (3S) -3-hydroxymethyl-7-oxopyridobenzoxazine 6-strengthene rubonate derivative can be produced industrially safely and inexpensively.
  • (3R) -3-Fluoromethyl-7-oxopyridobenzoxazine 6-carboxylic acid derivatives having a 4-substituted 3-cyclopropylaminomethylvirylyl group with excellent antibacterial activity and safety are industrially safe and It can be manufactured at low cost.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention provides an industrially advantageous process for the production of (3S)-3-hydroxymethyl-7- oxopyridobenzoxazine-6-carboxylic ester derivatives useful as intermediates of (3R)-3-fluoromethyl-7-oxopyridobenzoxazine -6-carboxylic acid derivatives having 4-substituted-3-cyclo- propylaminomethylpyrrolidinyl groups which serve as antimicrobial agents. The process is represented by the following reaction scheme: (X) wherein R1 is hydrogen, fluoro, or lower alkyl; R2 is lower alkyl; X is hydrogen or halogeno; and Y is halogeno.

Description

明 細 書  Specification
(3S) - 3-ヒドロキシメチル一 7—ォキソピリドベンゾォキサジン一 6—力 ルボン酸エステルの製造方法  (3S) -3-Hydroxymethyl mono 7-oxopyridobenzoxazine mono 6-strength
技術分野  Technical field
[0001] 本発明は、安全で、強力な抗菌作用を示すだけでなぐ従来の抗菌剤が効力を示 しにく 、耐性菌に対して有効な 4 -置換— 3 -シクロプロピルアミノメチルビルリジ- ル基を有する(3R)—3—フルォロメチル— 7—ォキソピリドベンゾォキサジン— 6—力 ルボン酸誘導体の中間体である(3S)—3—ヒドロキシメチルー 7—ォキソピリドベンゾ ォキサジン— 6—カルボン酸エステル誘導体の製造方法に関する。  [0001] The present invention is a 4-substituted 3-cyclopropylaminomethyl virylidine which is effective against resistant bacteria, because the conventional antibacterial agent which does not only exhibit a safe and strong antibacterial activity is effective. -(3R) -3-Fluoromethyl-7-oxopyridobenzoxazine with 6-groups (6S) (3S) -3-Hydroxymethyl-7-oxopyridobenzoxazine, an intermediate of rubonic acid derivatives — It relates to a method for producing a 6-carboxylic acid ester derivative.
背景技術  Background art
[0002] ノルフロキサシンの開発以来、ニューキノロンと呼ばれるキノロンカルボン酸系抗菌 剤の開発が全世界で行われ、キノロンカルボン酸系抗菌剤は現在感染症治療の重 要な位置を占めるまでに発展している。  [0002] Since the development of norfloxacin, the development of a quinolone carboxylic acid antibacterial agent called new quinolone has been carried out all over the world. .
[0003] 近年になってグラム陽性菌を中心に各種抗菌剤に耐性を示すメチシリン耐性黄色 ブドウ球菌(MRSA)、ペニシリン耐性肺炎球菌(PRSP)あるいはバンコマイシン耐 性腸球菌 (VRE)などが増加し、治療の大きな妨げとなっている。従来のキノロンカル ボン酸系抗菌剤はグラム陽性菌に対する抗菌力が本質的に弱いため、これらの耐性 菌に対する治療薬として十分な効力を有しているとは言い難い。さらにキノロンカル ボン酸系抗菌剤に対し耐性を示す黄色ブドウ球菌 (QRSA)の増カロも治療をさらに困 難なものにしている。  [0003] Recently, methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), and vancomycin-resistant enterococci (VRE), which are resistant to various antibacterial agents, mainly gram-positive bacteria, have increased. This is a major hindrance to treatment. Since conventional quinolone carboxylic acid antibacterial agents are inherently weak in antibacterial activity against Gram-positive bacteria, it cannot be said that they have sufficient efficacy as therapeutic agents against these resistant bacteria. Furthermore, the increased calorific value of Staphylococcus aureus (QRSA), which is resistant to quinolone carboxylic acid antibacterial agents, makes treatment even more difficult.
[0004] 係る実情に鑑み、本発明者らは抗菌力や安全性に優れた 4 置換 3—シクロプ 口ピルアミノメチルビルリジ-ル基を有する(3R)—3—フルォロメチル一 7—ォキソピ リドベンゾォキサジン 6—力ルボン酸誘導体を開示した (特許文献 1)。 4 置換 3 —シクロプロピルアミノメチルビルリジ-ル基を有する(3R)—3—フルォロメチル— 7 ォキソピリドベンゾォキサジン 6—力ルボン酸誘導体のきわめて有用な中間体で ある( 3S)— 3—ヒドロキシメチル 7—ォキソピリドベンゾォキサジン 6—カルボン 酸エステル誘導体は、ニトロフ ノール誘導体を出発原料に用いてラセミ体を製造し 、さらに高速液体クロマトグラフィーを使用してラセミ体を光学分割して製造している 例が報告されている (特許文献 2、非特許文献 1)。し力しながら、効率良くかつ純度 良く(3S)— 3—ヒドロキシメチルー 7—ォキソピリドベンゾォキサジン 6—力ルボン 酸エステル誘導体を得ることが困難であった。 [0004] In view of such circumstances, the present inventors have (3R) -3-fluoromethyl-1,7-oxopyridobenzo having a 4-substituted 3-cyclopyraminomethylvirylyl group excellent in antibacterial activity and safety. Oxazine 6-powered rubonic acid derivatives have been disclosed (Patent Document 1). 4 (3-R) -3-Fluoromethyl-7-oxopyridobenzoxazine with 6-substituted 3-cyclopropylaminomethylvirylidyl group is a very useful intermediate of 3 rubonic acid derivatives (3S) -3 —Hydroxymethyl 7-oxopyridobenzoxazine 6-carboxylate derivative is a racemic compound produced using a nitrophenol derivative as a starting material. In addition, there have been reported examples in which a racemate is optically resolved using high performance liquid chromatography (Patent Document 2, Non-Patent Document 1). However, it was difficult to obtain (3S) -3-hydroxymethyl-7-oxopyridobenzoxazine 6-strengthene carboxylic acid ester derivatives efficiently and with high purity.
特許文献 1: WO03Z078439ノ ンフレット  Patent Document 1: WO03Z078439 Nonfret
特許文献 2:特開昭 59 - 1489号公報  Patent Document 2: JP 59-1489
非特許文献 l : Chem. Pharm. Bull, 1987, 35, 1896-1902.  Non-patent literature l: Chem. Pharm. Bull, 1987, 35, 1896-1902.
発明の開示  Disclosure of the invention
発明が解決しょうとする課題  Problems to be solved by the invention
[0005] 本発明が解決しょうとする課題は、安全で、強力な抗菌作用を示すだけでなぐ従 来の抗菌剤が効力を示しにく Vヽ耐性菌に対して有効な 4 置換 3—シクロプロピル アミノメチルビルリジ-ル基を有する(3R)— 3—フルォロメチルー 7—ォキソピリドべ ンゾォキサジン 6—力ルボン酸誘導体の中間体である(3S)— 3—ヒドロキシメチル - 7-ォキソピリドベンゾォキサジン— 6—カルボン酸エステル誘導体の工業的に優 れた製造方法を提供することにある。 [0005] The problem to be solved by the present invention is that a conventional antibacterial agent that not only exhibits a safe and strong antibacterial action, but is not effective. (3R) — 3-Hydroxymethyl-7-oxopyridobenzox, which is an intermediate of (3R) — 3-Fluoromethyl-7-oxopyridobenzoxazine 6-strength rubonic acid derivative with propyl aminomethyl virylyl group It is an object of the present invention to provide an industrially excellent method for producing sasine-6-carboxylic acid ester derivatives.
課題を解決するための手段  Means for solving the problem
[0006] 即ち、本発明は一般式(1) That is, the present invention relates to the general formula (1)
[0007] [化 1] [0007] [Chemical 1]
Figure imgf000004_0001
Figure imgf000004_0001
[0008] (式中、 R1は水素原子、フッ素原子または低級アルキル基を、 R2は低級アルキル基 を、 Xは水素原子またはハロゲン原子を、 Yはハロゲン原子を表す。)で示されるベン ゾィル酢酸エステル誘導体をオルトギ酸エステルと反応させた後、式(2) [0008] (wherein R1 represents a hydrogen atom, a fluorine atom or a lower alkyl group, R2 represents a lower alkyl group, X represents a hydrogen atom or a halogen atom, and Y represents a halogen atom) After reacting the ester derivative with orthoformate, the formula (2)
[0009] [化 2]
Figure imgf000005_0001
[0009] [Chemical 2]
Figure imgf000005_0001
[0010] で示される (2R)—2—ァミノプロパノール誘導体を反応させ、一般式(3)  [0010] (2R) -2-aminopropanol derivative represented by the general formula (3)
[0011] [化 3] [0011] [Chemical 3]
Figure imgf000005_0002
Figure imgf000005_0002
(式中、 Rl、 R2、 Xおよび Yは前記定義に同じ。)で示される 2—べンゾィルー 3— [ ( 2R) - 2- [3 - (2—テトラヒドロビラ-ル)一 1—ヒドロキシ]プロピル]アミノアクリル酸 エステル誘導体を製造し、得られた一般式(3)で示される 2—ベンゾィル—3— [ (2R ) - 2- [3— (2—テトラヒドロビラ-ル)一 1—ヒドロキシ]プロピル]アミノアクリル酸ェ ステル誘導体を閉環して、一般式 (4) (Wherein Rl, R2, X and Y are the same as defined above) 2-Benzoyl 3-— [(2R)-2- [3- (2-Tetrahydrobiral) mono 1-hydroxy] 2-Propyl] aminoacrylic acid ester derivative and the resulting 2-benzoyl-3- [[2R)-2- [3— (2-tetrahydrobiral) mono 1-hydroxy compound represented by the general formula (3) ] Propyl] aminoacrylic acid ester
[0012] [化 4]  [0012] [Chemical 4]
Figure imgf000005_0003
Figure imgf000005_0003
[0013] (式中、 Rl、 R2、 Xおよび Yは前記定義に同じ。)で示される(3R)— 3—(2—テトラヒ ドロビラニル)ォキシメチルピリドベンゾォキサジンカルボン酸エステル誘導体を製造 した後、前記一般式 (4)で示される(3R)—3— (2—テトラヒドロビラニル)ォキシメチ ルピリドベンゾォキサジンカルボン酸エステル誘導体力 テトラヒドロビラ二ル基を除 去することを特徴とする一般式 (5)  [0013] (wherein Rl, R2, X and Y are the same as defined above) (3R) -3- (2-tetrahydroviranyl) oxymethylpyridobenzoxazine carboxylic acid ester derivative After the production, the (3R) -3- (2-tetrahydroviranyl) oxymethylpyridobenzoxazine carboxylic acid ester derivative represented by the general formula (4) is characterized by removing the tetrahydrovillaryl group. General formula (5)
[0014] [化 5]
Figure imgf000006_0001
[0014] [Chemical 5]
Figure imgf000006_0001
[0015] (式中、 Rl、 R2、 Xおよび Yは前記定義に同じ。)で示される(3S)— 3 ヒドロキシメ チル 9 , 10-ジフルォロ 7 ォキソピリドベンゾォキサジン 6 カルボン酸エス テルの製造方法に関するものである。  [0015] (wherein Rl, R2, X and Y are the same as defined above) (3S) —3 hydroxymethyl 9, 10-difluoro 7-oxopyridobenzoxazine 6 carboxylate ester It is related with the manufacturing method.
発明の効果  The invention's effect
[0016] 本発明方法により(3S)— 3 ヒドロキシメチルー 7 ォキソピリドベンゾォキサジン  [0016] According to the method of the present invention, (3S) -3 hydroxymethyl-7-oxopyridobenzoxazine
6—力ルボン酸エステル誘導体を工業的に安全かつ安価に製造することができる ので、この化合物を原料として耐性菌に対する抗菌力や安全性に優れた 4 置換 3—シクロプロピルアミノメチルビルリジ-ル基を有する(3R)—3—フルォロメチル— 7 ォキソピリドベンゾォキサジン 6—カルボン酸誘導体を工業的に安全かつ安価 に製造することができる。  Since 6-strength rubonic acid ester derivatives can be produced industrially safely and inexpensively, this compound is used as a raw material for 4-substituted 3-cyclopropylaminomethyl virylylol, which has excellent antibacterial activity and safety against resistant bacteria. A (3R) -3-fluoromethyl-7-oxopyridobenzoxazine 6-carboxylic acid derivative having a group can be produced industrially safely and inexpensively.
発明を実施するための最良の形態  BEST MODE FOR CARRYING OUT THE INVENTION
[0017] 本発明方法の第一工程は、前記一般式(1)で表されるベンゾィル酢酸エステル誘 導体にオルトギ酸ェチルなどのオルトギ酸エステル類を無水酢酸などのカルボン酸 無水物の存在下で、通常 0〜200°C、好ましくは 50〜150°Cの温度で、通常、 10分 〜50時間、好ましくは 1時間〜 10時間混合撹拌した後、前記式(2)で表される(2R) 2 ァミノプロパノール誘導体を適当な溶媒中で、通常 0〜150°C、好ましくは 0〜 100°Cの温度で、通常、 10分〜 50時間、好ましくは 30分〜 10時間混合撹拌するこ とにより実施できる。前記一般式(1)中 R1における低級アルキル基としては、例えば メチル基、ェチル基、プロピル基、イソプロピル基あるいはシクロプロピル基を挙げる ことができる。また前記一般式(1)中、 R2の低級アルキル基としては、例えばメチル 基、ェチル基、プロピル基、イソプロピル基、 tert ブチル基あるいはベンジル基を 挙げることができる。さらに、前記一般式(1)中 Xにおけるハロゲン原子としては、例 えばフッ素原子、塩素原子、臭素原子あるいはヨウ素原子を挙げることができる。さら にまた前記一般式(1)中、 Yのハロゲン原子としては、例えばフッ素原子、塩素原子 、臭素原子あるいはヨウ素原子を挙げることができる。 [0017] In the first step of the method of the present invention, an orthoformate such as ethyl orthoformate is added to a benzoyl acetate derivative represented by the general formula (1) in the presence of a carboxylic acid anhydride such as acetic anhydride. In general, the mixture is stirred at a temperature of 0 to 200 ° C, preferably 50 to 150 ° C, usually 10 minutes to 50 hours, preferably 1 hour to 10 hours, and then expressed by the above formula (2) (2R ) 2 The aminopropanol derivative is mixed and stirred in an appropriate solvent at a temperature of usually 0 to 150 ° C, preferably 0 to 100 ° C, usually 10 minutes to 50 hours, preferably 30 minutes to 10 hours. And can be implemented. Examples of the lower alkyl group represented by R1 in the general formula (1) include a methyl group, an ethyl group, a propyl group, an isopropyl group, and a cyclopropyl group. In the general formula (1), examples of the lower alkyl group represented by R2 include a methyl group, an ethyl group, a propyl group, an isopropyl group, a tert butyl group, and a benzyl group. Furthermore, examples of the halogen atom in X in the general formula (1) include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom. Furthermore, in the general formula (1), examples of the halogen atom for Y include a fluorine atom and a chlorine atom. And bromine atom or iodine atom.
[0018] この際、オルトギ酸エステル、カルボン酸無水物および前記式(2)で表される化合 物は、前記一般式(1)の化合物に対し、等モル以上、好ましくは 1〜10倍モル量の 割合で使用することができる。本反応で使用される溶媒としては、反応に影響を及ぼ さないものであればいずれでも使用することができ、たとえばベンゼン、トルエン、キ シレンなどの芳香族炭化水素類;ジェチルエーテル、ジイソプロピルエーテル、テトラ ヒドロフラン、ジォキサンなどのエーテル類;ペンタン、へキサンなどの脂肪族炭化水 素類;ジクロロメタン、クロ口ホルムなどのハロゲン化炭化水素類;メタノール、エタノー ル、プロパノールなどのアルコール類;ジメチルホルムアミド、 1ーメチルー 2—ピロリド ンなどのアミド類;ジメチルスルホキシドなどのスルホキシド類が挙げられる。  [0018] At this time, the orthoformate ester, the carboxylic acid anhydride and the compound represented by the formula (2) are used in an amount of equimolar or more, preferably 1 to 10 moles relative to the compound of the general formula (1). Can be used in proportion of quantity. Any solvent can be used as the solvent used in this reaction as long as it does not affect the reaction. For example, aromatic hydrocarbons such as benzene, toluene, xylene, etc .; jetyl ether, diisopropyl ether Ethers such as tetrahydrofuran and dioxane; aliphatic hydrocarbons such as pentane and hexane; halogenated hydrocarbons such as dichloromethane and chloroform; alcohols such as methanol, ethanol and propanol; dimethylformamide; Amides such as 1-methyl-2-pyrrolidone; and sulfoxides such as dimethyl sulfoxide.
[0019] 本発明方法の第二工程は前記一般式 (3)で表される 2 べンゾィルー 3— [ (2R) [0019] The second step of the method of the present invention is a 2-benzoyl 3-[(2R) represented by the general formula (3).
-2- [3- (2—テトラヒドロビラ-ル)一 1—ヒドロキシ]プロピル]アミノアクリル酸エス テル誘導体を塩基の存在下または不存在下に、通常 0〜200°C、好ましくは 0〜150 °Cの温度で、通常、 10分〜 50時間、好ましくは 30分〜 24時間混合撹拌することに より実施される。本反応で使用される塩基としては、たとえば水素化ナトリウム、水素 化カリウム、水素化カルシウムなどの金属水素化物;水酸ィ匕ナトリウム、水酸化力リウ ム、炭酸ナトリウム、炭酸カリウム、炭酸水素ナトリウムなどの無機塩基;ナトリウムメトキ シド、ナトリウムエトキシド、カリウム tert—ブトキシドなどのアルコキシド類;フッ化ナトリ ゥム、フッ化カリウム、フッ化セシウムなどの金属フッ化物;トリェチルァミン、ジイソプロ ピルェチルァミン、 1, 8 ジァザビシクロ [5, 4, 0]ゥンデ力一 7 ェンなどの有機塩 基が挙げられる。これらの塩基は、通常、前記一般式 (3)で表される化合物に対して 等モル以上、好ましくは 1〜2倍モル量の割合で使用することができる。また、上記反 応に使用される溶媒としては、反応に影響を及ぼさないものであればいずれでも使 用することができ、たとえばベンゼン、トルエン、キシレンなどの芳香族炭化水素類; ジェチルエーテル、ジイソプロピルエーテル、テトラヒドロフラン、ジォキサンなどのェ 一テル類;ペンタン、へキサンなどの脂肪族炭化水素類;ジクロロメタン、クロ口ホルム などのハロゲン化炭化水素類;メタノール、エタノール、プロパノールなどのアルコー ル類;ジメチルホルムアミド、 1 メチル 2—ピロリドンなどのアミド類;ジメチルスルホ キシドなどのスルホキシド類が挙げられる。 -2- [3- (2-Tetrahydrovinyl) mono 1-hydroxy] propyl] aminoacrylic acid ester derivative is usually 0 to 200 ° C., preferably 0 to 150 in the presence or absence of a base. It is usually carried out by mixing and stirring at a temperature of ° C for 10 minutes to 50 hours, preferably 30 minutes to 24 hours. Examples of the base used in this reaction include metal hydrides such as sodium hydride, potassium hydride, and calcium hydride; sodium hydroxide, sodium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, and the like. Alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide; metal fluorides such as sodium fluoride, potassium fluoride, cesium fluoride; triethylamine, diisopropylpropylamine, 1,8 diazabicyclo Organic bases such as 5, 4, 0] unde. These bases are usually used in an amount of equimolar or more, preferably 1 to 2 times the molar amount of the compound represented by the general formula (3). As the solvent used in the above reaction, any solvent that does not affect the reaction can be used. For example, aromatic hydrocarbons such as benzene, toluene, xylene, etc .; Ethers such as diisopropyl ether, tetrahydrofuran and dioxane; aliphatic hydrocarbons such as pentane and hexane; halogenated hydrocarbons such as dichloromethane and chloroform; alcohols such as methanol, ethanol and propanol; dimethyl Amides such as formamide and 1-methyl 2-pyrrolidone; dimethylsulfo And sulfoxides such as xoxide.
[0020] 本発明方法の第三工程は、前記一般式 (3)で表される(3R) - 3- (2—テトラヒドロ ビラ-ル)ォキシメチルピリドベンゾォキサジンカルボン酸エステル誘導体の 2—テトラ ヒドロビラ-ル基を脱離し、前記一般式 (4)で表される(3S)— 3—ヒドロキシメチルー 7 ォキソピリドベンゾォキサジン 6—カルボン酸エステル誘導体を製造する工程 である。  [0020] In the third step of the method of the present invention, the (3R) -3- (2-tetrahydrobiral) oxymethylpyridobenzoxazine carboxylic acid ester derivative represented by the general formula (3) is used. This is a process for producing a (3S) -3-hydroxymethyl-7oxopyridobenzoxazine 6-carboxylic acid ester derivative represented by the general formula (4) by eliminating 2-tetrahydrobiral group. .
[0021] 2—テトラヒドロビラ-ル基を脱離するには、通常の方法を採用すればよぐ前記一 般式(3)で表される化合物を無溶媒あるいは適当な溶媒中で酸と通常 0〜200°C、 好ましくは 0〜150°Cの温度で、通常、 10分〜 50時間、好ましくは 30分〜 24時間混 合撹拌することにより実施される。本反応で使用される酸としては、たとえば、塩酸、 硫酸、臭化水素酸、リン酸などの無機酸;ギ酸、酢酸、トリフルォロ酢酸、 p トルエン スルホン酸、メタンスルホン酸などの有機酸が挙げられる。また、上記反応に使用さ れる溶媒としては、反応に影響を及ぼさないものであればいずれでも使用することが でき、たとえば水;メタノール、エタノール、プロパノールなどのアルコール類;テトラヒ ドロフラン、ジォキサンなどのエーテル類;アセトン、メチルェチルケトンなどのケトン 類が挙げられ、これらの溶媒は単独である 、は混合して用いられる。  [0021] In order to remove the 2-tetrahydrovinyl group, a usual method may be adopted. The compound represented by the general formula (3) is usually used in the absence of a solvent or in an appropriate solvent with an acid. It is carried out by mixing and stirring at a temperature of 0 to 200 ° C, preferably 0 to 150 ° C, usually 10 minutes to 50 hours, preferably 30 minutes to 24 hours. Examples of the acid used in this reaction include inorganic acids such as hydrochloric acid, sulfuric acid, hydrobromic acid, and phosphoric acid; organic acids such as formic acid, acetic acid, trifluoroacetic acid, p-toluenesulfonic acid, and methanesulfonic acid. . As the solvent used in the above reaction, any solvent that does not affect the reaction can be used. For example, water; alcohols such as methanol, ethanol, and propanol; ethers such as tetrahydrofuran and dioxane. And ketones such as acetone and methyl ethyl ketone, and these solvents are used alone or in combination.
[0022] 本発明方法により出発原料としてラセミ体の 2—ァミノプロパノール誘導体を使用す ればラセミ体の 3—ヒドロキシメチルー 7—ォキソピリドベンゾォキサジン 6—カルボ ン酸エステル誘導体を、 (2S)—2 ァミノプロパノール誘導体を使用すれば(3R) - 3 -ヒドロキシメチル— 7—ォキソピリドベンゾォキサジン— 6—カルボン酸エステル誘 導体を製造することができる。  If a racemic 2-aminopropanol derivative is used as a starting material according to the method of the present invention, a racemic 3-hydroxymethyl-7-oxopyridobenzoxazine 6-carboxylate derivative is obtained. If a (2S) -2 aminopropanol derivative is used, a (3R) -3-hydroxymethyl-7-oxopyridobenzoxazine-6-carboxylic acid ester derivative can be produced.
[0023] 実施例  [0023] Examples
次に本発明を実施例をもって詳細に説明する。  Next, the present invention will be described in detail with reference to examples.
<参考例 1 >  <Reference Example 1>
(2R) 2 アミノー 3—(2—テトラヒドロビラニル)ォキシプロパノールの合成  Synthesis of (2R) 2 amino-3- (2-tetrahydroviranyl) oxypropanol
第一工程:  First step:
L—セリンメチルエステル塩酸塩(195g)を無水ジクロロメタン(973mL)に懸濁し、 3, 4 ジヒドロ 2H ピラン(158g)および p トルエンスルホン酸 1水和物(4. 76g )を加え、室温で 20時間撹拌した。析出した結晶を濾取し、ジクロロメタンで洗浄後、 減圧乾燥し、白色粉末の O— (2—テトラヒドロビラ-ル)—L—セリンメチルエステル 塩酸塩(20 lg)を得た。L-serine methyl ester hydrochloride (195 g) was suspended in anhydrous dichloromethane (973 mL), and 3, 4 dihydro 2H pyran (158 g) and p toluenesulfonic acid monohydrate (4.76 g) ) Was added and stirred at room temperature for 20 hours. The precipitated crystals were collected by filtration, washed with dichloromethane, and dried under reduced pressure to obtain white powder of O- (2-tetrahydrovinyl) -L-serine methyl ester hydrochloride (20 lg).
— NMR(DMSO— d ): δ  — NMR (DMSO— d): δ
6  6
1. 10— 2.02(m、 6H)、 3.41— 3.90(m、 3H)、 3.76(s、 3H)、 4.02(dd、J = 10.8Hz、 3.5Hz, 1H)、 4.35(dd、J = 3.5Hz、 3. OHz、 6H)、 4.51—4.72 (m、 1H) .  1.10—2.02 (m, 6H), 3.41—3.90 (m, 3H), 3.76 (s, 3H), 4.02 (dd, J = 10.8Hz, 3.5Hz, 1H), 4.35 (dd, J = 3.5Hz 3.OHz, 6H), 4.51-4.72 (m, 1H).
MS (CI+) m/z: 204 (M+ +H) .  MS (CI +) m / z: 204 (M + + H).
第二工程: Second step:
O— (2—テトラヒドロビラ-ル)—L—セリンメチルエステル塩酸塩(288g)を水素化 リチウムアルミニウム(91. lg)の無水テトラヒドロフラン(2400mL)懸濁液中に少量 ずつ加えた後、室温で 2時間撹拌し、さらに 2時間加熱還流した。反応混合物に氷水 冷下で水酸化カリウム(34.6g)の水溶液(173mL)を加えた後、 30分加熱還流した 。反応混合物中の不溶物を濾去し、不溶物をテトラヒドロフラン(lOOOmL)で洗浄し た。濾液と洗浄液を合わせ、減圧濃縮し、残渣をジクロロメタン(lOOmL)に溶解した 。ジクロロメタン溶液を 0.5molZL水酸化ナトリウム水溶液(300mL)次いで飽和食 塩水(300mL)で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮し、淡黄色油状の (2R)—2—アミノー 3— (2—テトラヒドロビラ-ル)ォキシプロパノール(149g)を得た  O- (2-Tetrahydrovinyl) -L-serine methyl ester hydrochloride (288 g) was added in small portions to a suspension of lithium aluminum hydride (91. lg) in anhydrous tetrahydrofuran (2400 mL), and then at room temperature. The mixture was stirred for 2 hours and further heated to reflux for 2 hours. An aqueous solution (173 mL) of potassium hydroxide (34.6 g) was added to the reaction mixture under cooling with ice water, and the mixture was heated to reflux for 30 minutes. The insoluble material in the reaction mixture was removed by filtration, and the insoluble material was washed with tetrahydrofuran (lOOOOmL). The filtrate and washings were combined and concentrated under reduced pressure, and the residue was dissolved in dichloromethane (lOOmL). The dichloromethane solution was washed with 0.5 mol ZL aqueous sodium hydroxide solution (300 mL) and then saturated brine (300 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give (2R) -2-amino-3- (2— Tetrahydroviryl) oxypropanol (149 g) was obtained.
[α] =— 70.7° (c = l.09、メタノール) [α] = — 70.7 ° (c = l.09, methanol)
D  D
'H-NMRCCDCI ): δ  'H-NMRCCDCI): δ
3  Three
1.43-2.17(m、 6H)、 3.06— 3. ll(m、 1H)、 3.36(dd、J=10.3Hz, 4.9 Hz、 1H), 3.53(dd、J=10.4Hz、 6.4Hz、 1H)、 3.64(dd、J=10.7Hz, 4.9 Hz, 1H)、 3.74(dd、J=10. OHz、 5.9Hz、 1H)、 3.75— 3.90(m、 1H)、 4. 57-4.59 (m、 1H) .  1.43-2.17 (m, 6H), 3.06— 3.ll (m, 1H), 3.36 (dd, J = 10.3Hz, 4.9 Hz, 1H), 3.53 (dd, J = 10.4Hz, 6.4Hz, 1H), 3.64 (dd, J = 10.7Hz, 4.9 Hz, 1H), 3.74 (dd, J = 10. OHz, 5.9Hz, 1H), 3.75—3.90 (m, 1H), 4. 57-4.59 (m, 1H) .
MS (CI+) m/z: 219 (M+ +H) . MS (CI +) m / z: 219 (M + + H).
実施例 1 Example 1
2 - (2. 3. 4. 5 -テトラフルォ口べンゾィル)— 3—「(2R)— 2—「_3—し 2—テトラヒド' ロビラニル)ォキシ 1ーヒドロキシ Ίプロピル Ίアミノアクリル酸ェチルの合成 2-(2. 3. 4. 5 -Tetrafluorobenzoyl) — 3 — “(2R) — 2 —“ _ 3— and 2-tetrahydr ' Robilanyl) oxy 1-hydroxy Ίpropyl Ίamino acrylate synthesis
2, 3, 4, 5—テトラフルォロベンゾィル酢酸ェチル(220g)、オルトギ酸ェチル(20 8mL)および無水酢酸(197mL)を混合し、 115〜120°Cで 3時間撹拌した後、減圧 濃縮した。残渣をエタノール(lOOOmL)に溶解し、氷水浴上で冷却しながら(2R) - 2 -ァミノ 3— (2 テトラヒドロビラ-ル)ォキシプロパノール( 16 lg)のエタノール( 300mL)溶液を滴下した。同温度で 1時間撹拌した後、反応混合物を減圧濃縮した 。残渣をシリカゲルカラム(溶出溶媒:ジクロロメタン→ジクロロメタン:メタノール = 10: 1)で精製し、黄色油状の 2— (2, 3, 4, 5—テトラフルォロベンゾィル)—3— [(2R) -2- [3— (2—テトラヒドロビラ-ル)ォキシ 1—ヒドロキシ]プロピル]アミノアクリル 酸ェチル(312g)を得た。  2, 3, 4, 5-tetrafluorobenzoyl ethyl acetate (220 g), ortho ethyl orthoformate (208 mL) and acetic anhydride (197 mL) were mixed and stirred at 115-120 ° C for 3 hours. Concentrated under reduced pressure. The residue was dissolved in ethanol (lOOOOmL), and a solution of (2R) -2-amino-3- (2 tetrahydrovinyl) oxypropanol (16 lg) in ethanol (300 mL) was added dropwise while cooling on an ice-water bath. After stirring at the same temperature for 1 hour, the reaction mixture was concentrated under reduced pressure. The residue was purified on a silica gel column (elution solvent: dichloromethane → dichloromethane: methanol = 10: 1) to give 2- (2, 3, 4, 5-tetrafluorobenzoyl) -3-3 [(2R ) -2- [3- (2-Tetrahydrovinyl) oxy 1-hydroxy] propyl] amino acrylate (312 g) was obtained.
[α] =—67.7° (c = 0.514、メタノーノレ) [α] = —67.7 ° (c = 0.514, methanol)
D  D
'H-NMRCCDCI ): δ  'H-NMRCCDCI): δ
3  Three
0.84-1.26(m、 3H)、 1.33— 2.12(m、 6H)、 2.40— 2.79(m、 1H)、 3.19 —4.31(m、 9H)、 4.46—4.78(m、 1H)、 6.84— 7. 15(m、 1H), 8.12— 8. 32 (m, 1H)、 9.36— 11.4(br、 1H) .  0.84-1.26 (m, 3H), 1.33-2.12 (m, 6H), 2.40-2.79 (m, 1H), 3.19-4.31 (m, 9H), 4.46-4.78 (m, 1H), 6.84-7.15 (m, 1H), 8.12-8.32 (m, 1H), 9.36-11.4 (br, 1H).
MS(El)m/z:449(M+). MS (El) m / z: 449 (M + ).
実施例 2 Example 2
2- (2. 3. 4 トリフルォロベンゾィル)一3—「(2R)— 2—「3— (2—テトラヒドロビラ ニル)ォキシ 1ーヒドロキシ Ίプロピル Ίアミノアクリル酸ェチルの合成 2- (2.3.4 Trifluorobenzoyl) 1 3-“(2R) — 2—“ 3-— (2-Tetrahydrovinyl) oxy 1-hydroxy Ίpropyl Ί Synthesis of aminoethyl acrylate
2, 3, 4 トリフルォロベンゾィル酢酸ェチル(10. Og)および(2R)— 2 アミノー 3 — (2—テトラヒドロビラ-ル)ォキシプロパノール (8.54g)を用い、実施例 1と同様に 反応を行い、黄色油状の 2— (2, 3, 4 トリフルォ口べンゾィル) 3— [(2R)—2— [3—(2—テトラヒドロビラ-ル)ォキシ 1 ヒドロキシ]プロピル]アミノアクリル酸ェチ ル(16.4g)を得た。  2, 3, 4 Trifluorobenzoyl acetate (10. Og) and (2R) -2 amino-3- (2-tetrahydrovinyl) oxypropanol (8.54 g) were used as in Example 1. 2- (2, 3, 4 trifluorobenzoyl) 3— [(2R) —2— [3 -— (2-tetrahydroviral) oxy 1 hydroxy] propyl] aminoacrylic acid Ethyl (16.4g) was obtained.
'H-NMRCCDCI ): δ  'H-NMRCCDCI): δ
3  Three
0.95(t、J = 7.3Hz、 0.8H)、 1.07(t、J = 7.3Hz、 2.4H)、 1.47—1.88(m、 6H)、 2.50-2.90(m、 1H)、 3.50— 3.56(1H, m)、 3.62— 3.69(m、 2H)、 3.77-3.86(m、 3H)、 3.89—4.13 (3H, m)、 4.62—4.64(m、 1H)、 6.94 -7.01 (m、 1H)、 7.06— 7. 12(0.8H, m)、 7.18— 7.24(0.2H, m)、 8.20 (d、J=14.2Hz, 0.2H)、 8.23(d、 J=13.8Hz、 0.8H)、 8.18— 9.65 (br, 0 .2H)、 11.0-11.2(br、 0.7H) . 0.95 (t, J = 7.3Hz, 0.8H), 1.07 (t, J = 7.3Hz, 2.4H), 1.47—1.88 (m, 6H), 2.50-2.90 (m, 1H), 3.50—3.56 (1H, m), 3.62-3.69 (m, 2H), 3.77-3.86 (m, 3H), 3.89-4.13 (3H, m), 4.62-4.64 (m, 1H), 6.94 -7.01 (m, 1H), 7.06-7.12 (0.8H, m), 7.18-7.24 (0.2H, m), 8.20 (d, J = 14.2Hz, 0.2H), 8.23 (d, J = 13.8 Hz, 0.8H), 8.18-9.65 (br, 0.2H), 11.0-11.2 (br, 0.7H).
実施例 3  Example 3
[0026] (3R)-9.10 ジフルオロー 2.3 ジヒドロ一 3—「(2—テトラヒドロビラニル)ォキシ メチル Ί— 7—ォキソ 7H ピリド「1.2.3-d. elf!.4Ίベンゾォキサジン一 6 力 ルボン酸ェチルの合成  [0026] (3R) -9.10 Difluoro-2.3 dihydro-1-3-((2-tetrahydroviranyl) oxymethyl Ί-7-oxo 7H pyrido 1.2.3-d. Elf! .4Ί benzoxazine 6 6 Composition
2- (2, 3, 4, 5—テトラフルォロベンゾィル)一3— [(2R)— 2— [3— (2—テトラヒ ドロビラ-ル)ォキシ 1—ヒドロキシ]プロピル]アミノアクリル酸ェチル(310g)を無水 ジメチルスルホキシド(1200mL)に溶解し、フッ化カリウム(スプレードライ品、 140g) を加え、 115〜120°Cで 5時間撹拌した。冷後、反応混合物にメタノール(600mL) を加えて希釈し、室温で 2時間放置した。析出晶を濾取し、メタノールで洗浄後、減 圧乾燥して淡褐色粉末の(3R)— 9, 10 ジフルォロ 2, 3 ジヒドロ 3— [(2— テトラヒドロビラ-ル)ォキシメチル ]—7—ォキソ 7H ピリド [1, 2, 3-d, e][l, 4 ]ベンゾォキサジン 6 カルボン酸ェチル( 176g)を得た。  2- (2, 3, 4, 5—Tetrafluorobenzoyl) 1-3— [(2R) — 2— [3— (2-Tetrahydroxyl) oxy 1-hydroxy] propyl] aminoacrylic acid Ethyl (310 g) was dissolved in anhydrous dimethyl sulfoxide (1200 mL), potassium fluoride (spray-dried product, 140 g) was added, and the mixture was stirred at 115 to 120 ° C for 5 hours. After cooling, the reaction mixture was diluted with methanol (600 mL) and allowed to stand at room temperature for 2 hours. The precipitated crystals were collected by filtration, washed with methanol, and dried under reduced pressure to give (3R) -9,10 difluoro 2,3 dihydro 3-[[2-tetrahydroviraloxy) methyl] -7-oxo. 7H pyrido [1,2,3-d, e] [l, 4] benzoxazine 6 Ethyl carboxylate (176 g) was obtained.
[α] =— 103° (c = 0.516、クロ口ホルム).  [α] = — 103 ° (c = 0.516, black mouth form).
D D
MS(El)m/z:409(M+). MS (El) m / z: 409 (M + ).
元素分析値(%):C H FNO  Elemental analysis (%): C H FNO
20 21 2 6  20 21 2 6
計算値: C, 58.68;H, 5.17;N, 3.42  Calculated value: C, 58.68; H, 5.17; N, 3.42
実測値: C, 58.88;H, 5.37;N, 3.47.  Found: C, 58.88; H, 5.37; N, 3.47.
実施例 4  Example 4
[0027] ( 3R)— 10 フルォロ 2.3 ジヒドロ一 3—「(2—テトラヒドロビラ-ル)ォキシメチ ル Ί—7—ォキソ 7H—ピリド「1.2.3-d. elf!.4Ίベンゾォキサジン 6—カルボ ン酸ヱチルの合成  [0027] (3R) —10 Fluoro 2.3 dihydro-3 — “(2-tetrahydroviral) oxymethyl Ί—7—oxo 7H—pyrido” “1.2.3-d. Elf! .4Ίbenzoxazine 6-carboxanoic acid Synthesis of ヱ chill
水素化ナトリウム(60%油性、 2.91g)を脱水 N, N ジメチルホルムアミド(130m L)に懸濁し、室温で 2— (2, 3, 4 トリフルォロベンゾィル)—3— [(2R)— 2— [3— (2—テトラヒドロビラ-ル)ォキシ 1—ヒドロキシ]プロピル]アミノアクリル酸ェチル( 1 4.3g)の脱水 N, N ジメチルホルムアミド(20mL)溶液を滴下した。反応混合物を 室温で 1時間、さらに 85〜90°Cで 100分撹拌した後、減圧濃縮した。残渣に水(10 OmL)を加え、酢酸ェチル (400mL)で抽出した。酢酸ェチル層を水洗(lOOmL)し 、無水硫酸ナトリウムで乾燥後、減圧濃縮した。残渣をシリカゲルカラム (ジクロ口メタ ン:メタノール =25:1)で精製し、淡褐色固体の( 3R)— 10 フルォロ 2, 3 ジヒ ドロ一 3— [ ( 2—テトラヒドロビラ-ル)ォキシメチル] 7 ォキソ 7H ピリド [ 1 , 2 , 3-d, e][l, 4]ベンゾォキサジン 6—力ルボン酸ェチル(5.66g)を得た。 Sodium hydride (60% oily, 2.91 g) is suspended in dehydrated N, N dimethylformamide (130 mL) at room temperature, 2— (2, 3, 4 trifluorobenzoyl) —3— [(2R) — 2— [3- (2-Tetrahydrobiral) oxy 1-hydroxy] propyl] amino acrylate (14.3 g) in dehydrated N, N dimethylformamide (20 mL) was added dropwise. Reaction mixture The mixture was stirred at room temperature for 1 hour and further at 85 to 90 ° C for 100 minutes, and then concentrated under reduced pressure. Water (10 OmL) was added to the residue and extracted with ethyl acetate (400mL). The ethyl acetate layer was washed with water (lOOmL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified on a silica gel column (diclonal methane: methanol = 25: 1) to give a light brown solid (3R) —10 fluoro 2,3 dihydro-3-3 [[(2-tetrahydroviral) oxymethyl] 7 The oxo 7H pyrido [1,2,3-d, e] [l, 4] benzoxazine 6-strength ethyl boronate (5.66 g) was obtained.
MS(El)m/z:391(M+). MS (El) m / z: 391 (M + ).
元素分析値(%):C H FNO  Elemental analysis (%): C H FNO
20 22 6  20 22 6
計算値: C, 61.37;H, 5.67;N, 3.58  Calculated value: C, 61.37; H, 5.67; N, 3.58
実測値: C, 61.23;H, 5.50;N, 3.61.  Found: C, 61.23; H, 5.50; N, 3.61.
実施例 5  Example 5
[0028] (3S)— 9.10 ジフルオロー 2.3 ジヒドロ一 3 ヒドロキシメチル一 7—ォキソ 7 H ピリド「1.2.3-d. elf!.4Ίベンゾォキサジン 6 力ルボン酸ェチルの合成 (3R)-9, 10 ジフルォロ一 2, 3 ジヒドロ一 3— [(2—テトラヒドロビラ-ル)ォキ シメチル ]ー7 ォキソ 7H—ピリド [1, 2, 3-d, e][l, 4]ベンゾォキサジンー6— カルボン酸ェチル(174g)、 p—トルエンスルホン酸 '一水和物(4.03g)およびェタノ ール(3000mL)を混合し、 8.5時間加熱還流した後、室温で 16時間放置した。析 出した結晶を濾取し、エタノールで洗浄後、減圧濃縮して白色粉末の(3S) -9, 10 —ジフルォロ一 2, 3 ジヒドロ一 3 ヒドロキシメチル一 7—ォキソ 7H ピリド [1, 2 , 3-d, e][l, 4]ベンゾォキサジン 6—力ルボン酸ェチル(127g)を得た。  [0028] (3S) — 9.10 Difluoro-2.3 Dihydro-l-3 Hydroxymethyl-l 7-oxo 7 H-pyrido “1.2.3-d. Elf !. 2, 3 Dihydro-1-3-[(2-tetrahydrobiral) oxymethyl] -7-oxo 7H-pyrido [1, 2, 3-d, e] [l, 4] benzoxazine-6-carvone Ethyl acid (174 g), p-toluenesulfonic acid monohydrate (4.03 g), and ethanol (3000 mL) were mixed, heated to reflux for 8.5 hours, and then allowed to stand at room temperature for 16 hours. Filter, wash with ethanol, and concentrate under reduced pressure to give (3S) -9,10-difluoro-1,3-dihydro-1,3-hydroxymethyl-1-7-oxo 7H pyrido [1, 2, 3-d, e ] [l, 4] Benzoxazine 6-strength ethyl boronate (127 g) was obtained.
[α] =— 124° (c = l.03、 Ν, Ν ジメチルホルムアミド).  [α] = — 124 ° (c = l.03, Ν, ジ メ チ ル dimethylformamide).
D D
MS(El)m/z:325(M+). MS (El) m / z: 325 (M + ).
元素分析値(%): C H F NO ·Η O  Elemental analysis (%): C H F NO · Η O
15 13 2 5 2  15 13 2 5 2
計算値: C, 52.48;H, 4.40;N, 4.08  Calculated value: C, 52.48; H, 4.40; N, 4.08
実測値: C, 52.75;H, 4.33;N, 4.23.  Found: C, 52.75; H, 4.33; N, 4.23.
実施例 6  Example 6
[0029] (3S)— 10 フルォロ 2.3 ジヒドロ 3 ヒドロキシメチル 7 ォキソ 7H ピ リド「1.2.3 - d. elf!.4Ίベンゾォキサジン 6 カルボン酸ェチルの合成 (3R)—10 フルォロ一 2, 3 ジヒドロ一 3— [(2—テトラヒドロビラ-ル)ォキシメチ ル ]ー7 ォキソ 7H—ピリド [1, 2, 3-d, e][l, 4]ベンゾォキサジン 6 カルボ ン酸ェチル(5.46g)を用い、実施例 5と同様に反応を行い、白色固体の(3S)— 10 —フルォロ一 2, 3 ジヒドロ一 3 ヒドロキシメチル一 7—ォキソ 7H ピリド [1, 2, 3-d, e][l, 4]ベンゾォキサジン 6—力ルボン酸ェチル(3.94g)を得た。 [0029] (3S) — 10 Fluoro 2.3 Dihydro 3 Hydroxymethyl 7oxo 7H Pyridine “1.2.3-d. Elf! .4ΊBenzoxazine 6 Synthesis of Ethyl Carboxylate (3R) -10 Fluoro-1,3 dihydro-1,3-[(2-tetrahydroviral) oxymethyl] -7 oxo 7H-pyrido [1, 2, 3-d, e] [l, 4] benzoxazine 6 Ethyl carbonate (5.46 g) was used in the same manner as in Example 5 to obtain (3S) -10-Fluoro-1,3 dihydro-1,3 Hydroxymethyl-7-oxo 7H pyrido [1, 2 , 3-d, e] [l, 4] benzoxazine 6-strength ethyl boronate (3.94 g) was obtained.
MS(El)m/z:307(M+). MS (El) m / z: 307 (M + ).
元素分析値(%):C H FNO Elemental analysis (%): C H FNO
15 14 5  15 14 5
計算値: C, 58.63;H, 4.59;N, 4.56  Calculated value: C, 58.63; H, 4.59; N, 4.56
実測値: C, 58.35;H, 4.44 ;N, 4.55.  Found: C, 58.35; H, 4.44; N, 4.55.
産業上の利用可能性 Industrial applicability
本発明方法により(3S)— 3 ヒドロキシメチルー 7 ォキソピリドベンゾォキサジン 6—力ルボン酸エステル誘導体を工業的に安全かつ安価に製造することができる ので、この化合物を原料として耐性菌に対する抗菌力や安全性に優れた 4 置換 3—シクロプロピルアミノメチルビルリジ-ル基を有する(3R)—3—フルォロメチル— 7 ォキソピリドベンゾォキサジン 6—カルボン酸誘導体を工業的に安全かつ安価 に製造することができる。  According to the method of the present invention, (3S) -3-hydroxymethyl-7-oxopyridobenzoxazine 6-strengthene rubonate derivative can be produced industrially safely and inexpensively. (3R) -3-Fluoromethyl-7-oxopyridobenzoxazine 6-carboxylic acid derivatives having a 4-substituted 3-cyclopropylaminomethylvirylyl group with excellent antibacterial activity and safety are industrially safe and It can be manufactured at low cost.

Claims

請求の範囲 一般式 (1) Claim General formula (1)
[化 1]  [Chemical 1]
Figure imgf000014_0001
Figure imgf000014_0001
(式中、 R1は水素原子、フッ素原子または低級アルキル基を、 R2は低級アルキル基 を、 Xは水素原子またはハロゲン原子を、 Yはハロゲン原子を表す。)で示されるベン ゾィル酢酸エステル誘導体をオルトギ酸エステルと反応させた後、式(2) (Wherein R1 represents a hydrogen atom, a fluorine atom or a lower alkyl group, R2 represents a lower alkyl group, X represents a hydrogen atom or a halogen atom, and Y represents a halogen atom). After reacting with orthoformate, formula (2)
[化 2]
Figure imgf000014_0002
[Chemical 2]
Figure imgf000014_0002
で示される(2R)—2—ァミノプロパノール誘導体を反応させ、一般式(3) (2R) -2-Aminopropanol derivative represented by the general formula (3)
[化 3] [Chemical 3]
Figure imgf000014_0003
Figure imgf000014_0003
(式中、 Rl、 R2、 Xおよび Yは前記定義に同じ。)で示される 2—べンゾィルー 3— [ ( 2R) - 2- [3 - (2—テトラヒドロビラ-ル)一 1—ヒドロキシ]プロピル]アミノアクリル酸 エステル誘導体を製造し、得られた一般式(3)で示される 2—ベンゾィル—3— [ (2R ) - 2- [3— (2—テトラヒドロビラ-ル)一 1—ヒドロキシ]プロピル]アミノアクリル酸ェ ステル誘導体を閉環して、一般式 (4)  (Wherein Rl, R2, X and Y are the same as defined above) 2-Benzoyl 3-— [(2R)-2- [3- (2-Tetrahydrobiral) mono 1-hydroxy] 2-Propyl] aminoacrylic acid ester derivative and the resulting 2-benzoyl-3- [[2R)-2- [3— (2-tetrahydrobiral) mono 1-hydroxy compound represented by the general formula (3) [Propyl] amino acrylate ester ring closure to produce a compound of the general formula (4)
[化 4]
Figure imgf000015_0001
[Chemical 4]
Figure imgf000015_0001
(式中、 Rl、 R2、 Xおよび Yは前記定義に同じ。)で示される(3R) - 3 - (2—テトラヒ ドロビラニル)ォキシメチルピリドベンゾォキサジンカルボン酸エステル誘導体を製造 した後、前記一般式 (4)で示される(3R) - 3- (2—テトラヒドロビラニル)ォキシメチ ルピリドベンゾォキサジンカルボン酸エステル誘導体力 テトラヒドロビラ二ル基を除 去することを特徴とする一般式 (5)  (Wherein Rl, R2, X and Y are the same as defined above) after the production of (3R) -3- (2-tetrahydrobiranyl) oxymethylpyridobenzoxazine carboxylic acid ester derivative And (3R) -3- (2-tetrahydroviranyl) oxymethylpyridobenzoxazine carboxylic acid ester derivative represented by the above general formula (4) is characterized by removing the tetrahydrovillaryl group Formula (5)
[化 5] [Chemical 5]
Figure imgf000015_0002
Figure imgf000015_0002
(式中、 Rl、 R2、 Xおよび Yは前記定義に同じ。)で示される(3S) (Wherein Rl, R2, X and Y are the same as defined above) (3S)
チル 9 , 10-ジフルォロ 7 ォキソピリドベンゾォキサジン 6 Tyl 9, 10-difluoro 7-oxopyridobenzoxazine 6
テルの製造方法。 Tell production method.
PCT/JP2005/013251 2004-07-21 2005-07-19 Process for production of (3s)-3-hydroxymethyl-7-oxo- pyridobenzoxazine-6-carboxylic esters WO2006009143A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006529225A JPWO2006009143A1 (en) 2004-07-21 2005-07-19 Process for producing (3S) -3-hydroxymethyl-7-oxopyridobenzoxazine-6-carboxylic acid ester

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004212400 2004-07-21
JP2004-212400 2004-07-21

Publications (1)

Publication Number Publication Date
WO2006009143A1 true WO2006009143A1 (en) 2006-01-26

Family

ID=35785251

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/013251 WO2006009143A1 (en) 2004-07-21 2005-07-19 Process for production of (3s)-3-hydroxymethyl-7-oxo- pyridobenzoxazine-6-carboxylic esters

Country Status (2)

Country Link
JP (1) JPWO2006009143A1 (en)
WO (1) WO2006009143A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS591489A (en) * 1982-06-29 1984-01-06 Dai Ichi Seiyaku Co Ltd Pyridobenzoxazine derivative
JPS62452A (en) * 1985-06-22 1987-01-06 バイエル・アクチエンゲゼルシヤフト Manufacture of 1,8-bridged-4-quinolone-3-carboxylic acids, intermediates and use as drug
JPS62198685A (en) * 1986-02-26 1987-09-02 Kyorin Pharmaceut Co Ltd Quinolonecarboxylic acid derivative and production thereof
JPS62252772A (en) * 1986-01-21 1987-11-04 Kyorin Pharmaceut Co Ltd 8-alkoxyquinolonecarboxylic acid having excellent selective toxicity, its salt and production thereof
WO2003078439A1 (en) * 2002-03-18 2003-09-25 Kyorin Pharmaceutical Co., Ltd. 10-(3-cyclopropylaminomethyl-1-pyrrolidinyl)pyridobenzoxazinecarboxylic acid derivative effective against resistant bacterium

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS591489A (en) * 1982-06-29 1984-01-06 Dai Ichi Seiyaku Co Ltd Pyridobenzoxazine derivative
JPS62452A (en) * 1985-06-22 1987-01-06 バイエル・アクチエンゲゼルシヤフト Manufacture of 1,8-bridged-4-quinolone-3-carboxylic acids, intermediates and use as drug
JPS62252772A (en) * 1986-01-21 1987-11-04 Kyorin Pharmaceut Co Ltd 8-alkoxyquinolonecarboxylic acid having excellent selective toxicity, its salt and production thereof
JPS62198685A (en) * 1986-02-26 1987-09-02 Kyorin Pharmaceut Co Ltd Quinolonecarboxylic acid derivative and production thereof
WO2003078439A1 (en) * 2002-03-18 2003-09-25 Kyorin Pharmaceutical Co., Ltd. 10-(3-cyclopropylaminomethyl-1-pyrrolidinyl)pyridobenzoxazinecarboxylic acid derivative effective against resistant bacterium

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ATARASHI S. ET AL: "Synthesis and Antibacterial Activities of Optically Active Ofloxacin and its Fluoromethyl Derivative.", CHEM PHARM BULL., vol. 35, no. 5, 1987, pages 1896 - 1902, XP002991710 *
GREENE W. ET AL, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, 3RD EDITION., 1991, pages 31 - 34, XP002991711 *

Also Published As

Publication number Publication date
JPWO2006009143A1 (en) 2008-05-01

Similar Documents

Publication Publication Date Title
WO2019070059A1 (en) Method for stereoselectively producing substituted polycyclic pyridone derivative
JP2021503438A (en) Heterocyclic compounds as PAD inhibitors
KR20160047378A (en) Novel aminoalkylbenzothiazepine derivatives and use thereof
JP2017529378A (en) Methods and intermediates in the production of C5aR antagonists
US20100179319A1 (en) Process for production of optically active mirtazapine
CN103755722B (en) The synthetic method of a kind of Levofloxacin and Ofloxacine USP 23
JPH0588714B2 (en)
JP2013536798A5 (en)
WO2022107755A1 (en) Novel acridinium salt and method for producing same
KR100309871B1 (en) Process for Preparing (-)Pyridobenzoxazine Carboxylic Acid Derivatives
WO2006009143A1 (en) Process for production of (3s)-3-hydroxymethyl-7-oxo- pyridobenzoxazine-6-carboxylic esters
JP5065020B2 (en) Process for producing levofloxacin or a hydrate thereof
JP5597202B2 (en) 3- (biaryloxy) propionic acid derivatives
JP2000504352A (en) Pyrrolo [3,2-c] quinoline derivatives containing haloalkoxy groups and pharmaceutically acceptable salts thereof
JPWO2014051077A1 (en) Method for producing high purity nitrogen-containing heterocyclic compound
CN110016029B (en) Preparation method of 3-fluoro-1H-pyrrolo [2,3-b ] pyridine-2-carboxylic acid
JP2004099494A (en) Method for producing optically active tricyclic compound
JP2573269B2 (en) Optically active benzoxazine
JP2884094B2 (en) Novel method for solubilizing pyridonecarboxylic acid or its salt
CN109593068B (en) Intermediate of ROR gamma inhibitor and preparation method thereof
ES2819286T3 (en) Process for the large-scale production of 1-isopropyl-3-{5-[1-(3-methoxypropyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H- oxalate indazole
JP2769058B2 (en) Preparation of cyclopropane derivatives
JP2724383B2 (en) Method for producing (S) -benzoxazine derivative
JP4856408B2 (en) Method for producing α-thioester compound and production intermediate thereof
WO2010016851A1 (en) Process for selectively producing a pyridobenzoxazine carboxylic acid hemihydrate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006529225

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase